Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
24621
Beskrivning
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00864175
Länk
https://clinicaltrials.gov/show/NCT00864175
Nyckelord
Versioner (2)
- 2017-08-09 2017-08-09 -
- 2021-09-17 2021-09-17 -
Uppladdad den
9 augusti 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Metastatic Breast Cancer NCT00864175
Eligibility Metastatic Breast Cancer NCT00864175
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT00864175
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Secondary malignant neoplasm of female breast HER2/Neu Positive
Item
histologically or cytologically confirmed metastatic breast carcinoma that is her2 positive
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C2348909 (UMLS CUI [1,2])
Measurable Disease
Item
measurable disease as defined by the recist criteria
boolean
C1513041 (UMLS CUI [1])
Life Expectancy
Item
life expectancy greater than or equal to 6 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Antineoplastic Agents
Item
received any anticancer medications in the 28 days prior to enrollment into this study
boolean
C0003392 (UMLS CUI [1])
Antineoplastic Agents | Breast Carcinoma Excluded
Item
received any anticancer medications for cancers other than breast cancer within 6 months prior to enrollment in this study.
boolean
C0003392 (UMLS CUI [1])
C0678222 (UMLS CUI [2,1])
C2828389 (UMLS CUI [2,2])
C0678222 (UMLS CUI [2,1])
C2828389 (UMLS CUI [2,2])
Deep Vein Thrombosis
Item
history of deep venous thrombosis within the last year
boolean
C0149871 (UMLS CUI [1])
Medical contraindication Warfarin Low dose
Item
contraindication to low dose warfarin therapy
boolean
C1301624 (UMLS CUI [1,1])
C0043031 (UMLS CUI [1,2])
C0445550 (UMLS CUI [1,3])
C0043031 (UMLS CUI [1,2])
C0445550 (UMLS CUI [1,3])
Cardiomyopathy
Item
clinically significant cardiomyopathy
boolean
C0878544 (UMLS CUI [1])
INCB007839 | trastuzumab | lapatinib
Item
prior treatment with incb007839 or trastuzumab or lapatinib
boolean
C2830216 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])